Details

Last Funding Type

Series C

Last Funding Money Raised

$40M

Industries

Biotechnology,Medical,Therapeutics

Founded date

Jan 1, 1999

Number Of Employee

51 - 100

Operating Status

Active

Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.